Skip to content
S2393Senate2023-2024 SessionSame asA1962

Drug Rebates Go To Patients

Official title

“Relates to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale”

Sponsor Robert JacksonSD-31+7 co-sponsorsAffects Finance
Status
In Senate Committee
Finance
Impact
8/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Finance

What's happening

This bill requires health insurers in New York to pass at least 85% of prescription drug rebates directly to patients at the point of sale.

Why it matters

  1. Potential for significant out-of-pocket savings. By mandating that at least 85% of prescription drug rebates go directly to patients at the pharmacy counter, the bill could lower immediate costs for people filling prescriptions, rather than letting insurers or pharmacy benefit managers retain most of the rebate savings.

  2. Transparency and accountability requirements. Insurers and health plans must certify annually that they are in compliance, creating a paper trail for state oversight and making it harder for companies to quietly bypass the rule.

  3. Limits on disclosure to protect proprietary data. The bill restricts the public release of detailed rebate information, aiming to protect competitive pricing strategies, but this could also limit public scrutiny of how rebates are negotiated and distributed.

  4. Broad application to most health plans. The law applies to any insurer or employer plan regulated by New York State, meaning it covers a wide swath of New Yorkers and could standardize prescription drug cost-sharing practices across many types of coverage.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients with prescription drug deductibles or coinsurance

    Their cost sharing would be calculated at the point of sale using a drug price reduced by at least 85% of associated rebates.

  • Health insurers and state and local government employer plans

    They would have to apply the rebate-based pricing requirement and certify compliance annually to the superintendent by January 1.

  • Insurance regulators

    The superintendent would establish the certification form and receive annual attestations covering the prior calendar year.

  • Health care vendors and administrative contractors

    Those with access to insurers’ rebate information would be subject to confidentiality protections imposed by the insurers.

Headline styles

Drug Rebates Go To Patients

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Robert Jackson

Senator · Senate District 31

Chair, Civil Service And Pensions

History

  1. Reported and committed to finance
  2. Referred to insurance
  3. Print number 2393b
  4. Amend (t) and recommit to insurance
  5. Print number 2393a
  6. Amend and recommit to insurance
  7. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A1962Assembly

Give Drug Rebates to Patients

In Assembly Committee · Insurance · Sponsor Latrice Walker

Impact 8 · Significant0% to pass

Full text

4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

2393--B

2023-2024 Regular Sessions

IN SENATE

January 20, 2023

Introduced by Sens. JACKSON, HOYLMAN-SIGAL -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the insurance law and the public health law, in relation to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The insurance law is amended by adding a new section 3246 to read as follows:

§ 3246. Ensuring fairness in certain cost sharing. (a) As used in this section, the following terms shall have the following meanings:

(1) "Defined cost sharing" means a deductible payment or coinsurance amount imposed on an enrollee for a covered prescription drug under the enrollee's health plan.

(2) "Insurer" means any health insurance issuer that is subject to state law regulating insurance and offers health insurance coverage, as defined in 42 U.S.C. § 300gg-91, or any state or local governmental employer plan.

(3) "Price protection rebate" means a negotiated price concession that accrues directly or indirectly to the insurer, or other party on behalf of the insurer, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.

(4) "Rebate" means:

(A) Negotiated price concessions including but not limited to base price concessions, whether described as a rebate or otherwise, and reasonable estimates of any price protection rebates and performance-

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD05427-04-3

based price concessions that may accrue directly or indirectly to the insurer during the coverage year from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug, and

(B) Reasonable estimates of any negotiated price concessions, fees and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the insurer and serve to reduce the insurer's liabilities for a prescription drug.

(b) An enrollee's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least eighty-five percent of all rebates received, or to be received, in connection with the dispensing or administration of the prescription drug. Nothing shall preclude an insurer from decreasing an enrollee's defined cost sharing by an amount greater than that required under this subsection.

(c) An insurer shall submit to the superintendent by the first of January of each year a certification in a form to be established by the superintendent attesting that it has complied with the requirements of subsection (b) of this section for the prior calendar year.

(d) In complying with the provisions of this section, an insurer or its agents shall not publish or otherwise publicly reveal information regarding the actual amount of rebates an insurer receives on a product or therapeutic class of products, manufacturer, or pharmacy-specific basis. Such information shall be exempt from disclosure under section eighty-seven of the public officers law and shall not be disclosed directly or indirectly, or in a manner that would allow for the identification of an individual product, therapeutic class of products, or manufacturer, or in a manner that would have the potential to compromise the financial, competitive, or proprietary nature of such information. An insurer shall impose the confidentiality protections of this subdivision on any vendor or downstream third-party that performs health care or administrative services on behalf of the insurer that may receive or have access to rebate information.

§ 2. The insurance law is amended by adding a new section 4331 to read as follows:

§ 4331. Ensuring fairness in certain cost sharing. (a) As used in this section, the following terms shall have the following meanings:

(1) "Defined cost sharing" means a deductible payment or coinsurance amount imposed on an enrollee for a covered prescription drug under the enrollee's health plan.

(2) "Corporation" means any health insurance issuer that is subject to state law regulating insurance and offers health insurance coverage, as defined in 42 U.S.C. § 300gg-91, or any state or local governmental employer plan.

(3) "Price protection rebate" means a negotiated price concession that accrues directly or indirectly to the corporation, or other party on behalf of the corporation, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.

(4) "Rebate" means:

(A) Negotiated price concessions including but not limited to base price concessions, whether described as a rebate or otherwise, and reasonable estimates of any price protection rebates and performancebased price concessions that may accrue directly or indirectly to the corporation during the coverage year from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug, and

(B) Reasonable estimates of any negotiated price concessions, fees and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the corporation and serve to reduce the corporation's liabilities for a prescription drug.

(b) An enrollee's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least eighty-five percent of all rebates received, or to be received, in connection with the dispensing or administration of the prescription drug. Nothing shall preclude a corporation from decreasing an enrollee's defined cost sharing by an amount greater than that required under this subsection.

(c) A corporation shall submit to the superintendent by the first of January of each year a certification in a form to be established by the superintendent attesting that it has complied with the requirements of subsection (b) of this section for the prior calendar year.

(d) In complying with the provisions of this section, a corporation or its agents shall not publish or otherwise publicly reveal information regarding the actual amount of rebates a corporation receives on a product or therapeutic class of products, manufacturer, or pharmacy-specific basis. Such information shall be exempt from disclosure under section eighty-seven of the public officers law and shall not be disclosed directly or indirectly, or in a manner that would allow for the identification of an individual product, therapeutic class of products, or manufacturer, or in a manner that would have the potential to compromise the financial, competitive, or proprietary nature of such information. A corporation shall impose the confidentiality protections of this subdivision on any vendor or downstream third-party that performs health care or administrative services on behalf of the corporation that may receive or have access to rebate information.

§ 3. The public health law is amended by adding a new section 4417 to read as follows:

§ 4417. Ensuring fairness in certain cost sharing. 1. As used in this section, the following terms shall have the following meanings:

(a) "Defined cost sharing" means a deductible payment or coinsurance amount imposed on an enrollee for a covered prescription drug under the enrollee's health plan.

(b) "Organization" means any health insurance issuer that is subject to state law regulating insurance and offers health insurance coverage, as defined in 42 U.S.C. § 300gg-91, or any state or local governmental employer plan.

(c) "Price protection rebate" means a negotiated price concession that accrues directly or indirectly to the organization, or other party on behalf of the organization, in the event of an increase in the wholesale acquisition cost of a drug above a specified threshold.

(d) "Rebate" means:

(i) Negotiated price concessions including but not limited to base price concessions, whether described as a rebate or otherwise, and reasonable estimates of any price protection rebates and performancebased price concessions that may accrue directly or indirectly to the organization during the coverage year from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug, and

(ii) Reasonable estimates of any negotiated price concessions, fees and other administrative costs that are passed through, or are reasonably anticipated to be passed through, to the organization and serve to reduce the organization's liabilities for a prescription drug.

2. An enrollee's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least eighty-five percent of all rebates received, or to be received, in connection with the dispensing or administration of the prescription drug. Nothing shall preclude an organization from decreasing an enrollee's defined cost sharing by an amount greater than that required under this subdivision.

3. An organization shall submit to the superintendent by the first of January of each year a certification in a form to be established by the superintendent attesting that it has complied with the requirements of subdivision two of this section for the prior calendar year.

4. In complying with the provisions of this section, an organization or its agents shall not publish or otherwise publicly reveal information regarding the actual amount of rebates an organization receives on a product or therapeutic class of products, manufacturer, or pharmacy-specific basis. Such information shall be exempt from disclosure under section eighty-seven of the public officers law and shall not be disclosed directly or indirectly, or in a manner that would allow for the identification of an individual product, therapeutic class of products, or manufacturer, or in a manner that would have the potential to compromise the financial, competitive, or proprietary nature of such information. An organization shall impose the confidentiality protections of this subdivision on any vendor or downstream third-party that performs health care or administrative services on behalf of the organization that may receive or have access to rebate information.

§ 4. This act shall take effect immediately and apply to contracts issued, renewed or amended on or after January 1, 2023.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the public health law, in relation to requiring certain health insurance issuers to certify that at least a majority of prescription drug rebates are provided to patients at the point of sale

Purpose

To ensure patients benefit from substantial discounts that exist within the prescription drug supply chain.

Summary of provisions

Section 1 adds a new Section 3245 to Article 32 of the Insurance Law, defining "Defined cost sharing," "Insurer," "Price Protection Rebate," and "Rebate;" requiring individual and small group carriers to certify that at least a majority (greater than 85%) of prescription drug rebates are provided to patients at the point of sale.

Section 2 adds a new Section 4331 to Article 43 of the Insurance Law, defining "Defined cost sharing," "Insurer," "Price Protection Rebate," and "Rebate;" requiring individual and small group carriers to certify that at least a majority (greater than 85%) of prescription drug rebates are provided to patients at the point of sale.

Section 3 adds a new Section 4417 to Article 44 of the Public Health Law, defining "Defined cost sharing," "Insurer," "Price Protection Rebate," and "Rebate;" requiring individual and small group carriers to certify that at least a majority (greater than 85%) of prescription drug rebates are provided to patients at the point of sale.

Section 4 is the effective date.

Justification

The difference between list prices of prescription drugs and the net prices paid by pharmacy benefit managers and health insurers has been growing exponentially in recent years. While many entities benefit from these large negotiated discounts - estimated at $166 billion in 2018 one group gets the short end of the stick: patients.

As more and more health insurance benefit designs rely on coinsurance and deductibles, patients end up paying cost sharing on the list price of the drug even as their health plan is reaping significant discounts. Unlike negotiated discounts on other services like hospital care, these savings are not shared with patients in the deductible phase of a plan and patients often end up paying more than their health plan for a drug. Plans argue that the discounts are used to lower premiums for everyone, but patients with complex and chronic conditions end up carrying the biggest burden - exactly the opposite of how insurance should work. This bill strikes a careful balance, allowing rebates and discounts to be socialized and keep premiums down to a point, but also making sure some of those significant discounts are passed along to the place they're most important to patients - at the pharmacy counter.

West Virginia is currently the only state requiring drug rebates to be passed along to the patient at the point of sale. The legislation is considered the model for other states with rebates at 100% being passed along to patients. Many health plans have already implemented this option and have marketed this approach as good for patients and "worth it."

Legislative history

2021-2022: S.2006 - Referred to Insurance/A.5218-A - Referred to Insur- ance

2019-2020: S.6489 - Referred to Insurance/A.8310 - Referred to Insurance

State and local fiscal implications

None.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.